<html><body><h1>Can Hyperbaric Oxygen Therapy Be Used to Treat Children</h1><h1>after COVID-19? A Bibliographic Review</h1><div><p>Abstract: The coronavirus disease (COVID-19) epidemic is a public health emergency of international</p><p>concern. It was believed that SARS-CoV-2 virus was much less likely affect children. Statistics show</p><p>that children account for 2–13% of all COVID-19 patients in individual countries. In the youngest</p><p>population, acute respiratory failure is not as serious a problem as complications after COVID-19,</p><p>review. The Medline database (using the PubMed platform) and the Cochrane Clinical Trials database</p><p>were searched using the following keywords: hyperbaric oxygen therapy for children, treatment of</p><p>children with COVID-19, and use of HBOT in the treatment of children following COVID-19. Thirteen</p><p>publications that quantitatively and qualitatively described the efﬁcacy of HBOT application in the</p><p>treatment of pediatric diseases were eligible among the studies; those relating to the use of HBOT in</p><p>the treatment of children with COVID-19 and its complications were not found. The bibliographic</p><p>review showed that hyperbaric oxygen therapy can be used in the treatment of children after carbon</p><p>monoxide poisoning, with soft tissue necrosis, bone necrosis, after burns, or after skin transplant. No</p><p>evidence supported by research has been found in scientiﬁc journals on the effectiveness of the use</p><p>of hyperbaric oxygen therapy in children with a history of COVID-19 infection. Research data are</p><p>needed to develop evidence-driven strategies with regard to the use of HBOT therapy in the treatment</p><p>of children and to reduce the number of pediatric patients suffering because of complications after</p><p>COVID-19.</p><p>Yildiz et al.</p><p>(2021)</p><p>retrosp.</p><p>CO</p><p>poisoning</p><p>n = 93 TG</p><p>n = 238 CG</p><p>age < 19 years</p><p>HBOT</p><p>NBO treatment</p><p>Glasgow score,</p><p>leukocyte count,</p><p>troponin T level,</p><p>carboxyhemoglobin</p><p>level</p><p>- signiﬁcantly better</p><p>indices after HBO</p><p>therapy</p><p>1</p><p>2</p><p>3</p><p>4</p><p>Neheman et al.</p><p>(2020)</p><p>retrosp.</p><p>skin grafts</p><p>n = 7 TG</p><p>n = 14 CG</p><p>age < 18 years</p><p>Camison et al.</p><p>(2020)</p><p>retrosp.</p><p>skin grafts</p><p>age:</p><p>1.6–15.1 years</p><p>(mean age:</p><p>8.4 years)</p><p>- one HBOT session per</p><p>day for 5 days during</p><p>the 4 weeks before</p><p>surgery and 10</p><p>additional sessions</p><p>following the surgery</p><p>- session duration: 90 min</p><p>exposure to 100%</p><p>oxygen at a pressure of 2</p><p>ATA with 5 min air</p><p>breathing breaks every</p><p>20 min</p><p>- 2 HBOT sessions per</p><p>day, maximum 20</p><p>sessions</p><p>- session duration: 90 min</p><p>at 2.4 ATA</p><p>Chang et al.</p><p>(2020)</p><p>retrosp.</p><p>skin grafts</p><p>HBOT</p><p>[17]</p><p>[18]</p><p>standard</p><p>treatment</p><p>successful when graft</p><p>acceptance occurred</p><p>and graft shrinkage</p><p>was not observed</p><p>- positive result: all</p><p>patients in the study</p><p>group had good graft</p><p>acceptance without</p><p>shrinkage; in the control</p><p>group, 57% had good</p><p>graft acceptance and</p><p>were able to proceed to</p><p>the second stage, while</p><p>43% developed graft</p><p>shrinkage</p><p>not applicable</p><p>(no control</p><p>group)</p><p>successful when graft</p><p>acceptance occurred</p><p>without</p><p>complications</p><p>standard</p><p>treatment</p><p>(vasodilators</p><p>- examination of</p><p>patients every 3</p><p>weeks, then every</p><p>3 months</p><p>- successful when</p><p>- a positive result was</p><p>observed in all patients</p><p>[19]</p><p>- in the study group,</p><p>44/49 grafts were</p><p>successful</p><p>- in the control group,</p><p>[20]</p><p>Biddeci et al.</p><p>(2019)</p><p>retrosp.</p><p>osteonecrosis</p><p>n = 8 TG</p><p>n = 15 CG</p><p>age < 18 years</p><p>- at least 30 HBO</p><p>treatments at a pressure</p><p>of 2.5 ATA</p><p>- a course of sessions: 3</p><p>periods of 25 min with</p><p>100% oxygen alternated</p><p>with 5-min periods in</p><p>which air was</p><p>administered</p><p>standard</p><p>treatment</p><p>- MRI evaluation</p><p>Teksam et al.</p><p>(2019)</p><p>retrosp.</p><p>CO</p><p>poisoning</p><p>n = 16 TG</p><p>n = 29 CG</p><p>age < 19 years</p><p>(mean age:</p><p>9 years)</p><p>- HBOT session at 5 ATA,</p><p>session duration: 90 min  NBO treatment</p><p>Kawecki et al.</p><p>(2016)</p><p>retrosp.</p><p>e.g.,</p><p>necrotizing</p><p>soft-tissue</p><p>infection,</p><p>age: 10 months—</p><p>- HBOT session at 2 to 2.5</p><p>ATA,</p><p>- session duration: 55 to</p><p>122 min (monoplace</p><p>standard</p><p>treatment</p><p>assessment of</p><p>oxidative stress levels</p><p>and antioxidant</p><p>parameters based on</p><p>the examination of</p><p>blood and urine</p><p>samples; samples</p><p>collected:</p><p>- at admission,</p><p>- after normobaric</p><p>oxygen treatment</p><p>- after hyperbaric</p><p>oxygen treatment</p><p>evaluation of the</p><p>mean time of</p><p>hospitalization,</p><p>average time of skin</p><p>5</p><p>6</p><p>7</p><p>- at an advanced stage of</p><p>ON:</p><p>- no effect of HBO</p><p>therapy in MRI in the</p><p>early stage of ON:</p><p>- pain relief,</p><p>- disability relief,</p><p>- positive effect on</p><p>changes in MRI</p><p>morphology</p><p>- no signiﬁcant effect of</p><p>HBO therapy on</p><p>oxidative stress and</p><p>antioxidant parameters</p><p>was observed</p><p>- no signiﬁcant effect of</p><p>NBO therapy on</p><p>oxidative stress and</p><p>antioxidant parameters</p><p>was observed</p><p>- reduced length of</p><p>hospital stay</p><p>- reduced time to prepare</p><p>skin for the graft</p><p>[21]</p><p>[22]</p><p>[23]</p><p>- HBOT session at 2.4</p><p>ATA</p><p>- session duration:</p><p>140 min, including</p><p>100 min under pressure</p><p>NBO treatment</p><p>assessment of</p><p>carboxyhemoglobin</p><p>levels and period of</p><p>hospitalization</p><p>- signiﬁcantly lower</p><p>carboxyhemoglobin</p><p>levels</p><p>- signiﬁcantly shorter</p><p>hospitalization period</p><p>8</p><p>9</p><p>Yarar et al.</p><p>(2008)</p><p>retrosp.</p><p>CO</p><p>poisoning</p><p>Bernbeck et al.</p><p>(2004)</p><p>retrosp.</p><p>osteonecrosis</p><p>n = 38 TG</p><p>n = 36 CG</p><p>age:</p><p>1–17.8 years</p><p>n = 19 TG</p><p>n = 8 CG</p><p>mean age:</p><p>(range:</p><p>7 months to</p><p>16 years)</p><p>- an average of 45 HBO</p><p>treatments per patient</p><p>(min. 13, max. 80</p><p>treatments)</p><p>standard</p><p>treatment</p><p>10</p><p>Scherer et al.</p><p>(2000)</p><p>retrosp.</p><p>osteonecrosis</p><p>mean age TG</p><p>mean age CG</p><p>- an average of 43 HBO</p><p>treatments at 2.5 ATA</p><p>over a period of</p><p>6–12 weeks</p><p>- session duration:</p><p>130 min, including a</p><p>90-min oxygen</p><p>inhalation period</p><p>standard</p><p>treatment</p><p>- MRI scan</p><p>evaluation</p><p>performed every 3</p><p>months for the</p><p>radiological extent</p><p>of lesions</p><p>- assessment of pain</p><p>severity and</p><p>location</p><p>- MRI scan</p><p>evaluation on a</p><p>scoring system</p><p>(1–6 points)</p><p>independently by</p><p>two radiologists</p><p>- evaluation criteria</p><p>included size,</p><p>number, and</p><p>location of AON</p><p>[24]</p><p>[25]</p><p>[26]</p><p>children < 10 years</p><p>old—beneﬁcial effect of</p><p>HBOT:</p><p>- decrease in AON</p><p>- conversion of AON to</p><p>BME children > 10 years</p><p>old—no beneﬁcial effect</p><p>on BME</p><p>at an advanced stage of</p><p>AON:</p><p>- the positive role of</p><p>HBOT in pain relief</p><p>- no signiﬁcant changes in</p><p>MRI morphology in the</p><p>early stage of AON:</p><p>- positive effects on</p><p>discrete forms of AON,</p><p>especially on bone</p><p>edema</p><p>- a signiﬁcantly lower</p><p>death rate for children</p><p>12</p><p>Weisman et al.</p><p>(1998)</p><p>retrosp.</p><p>(among</p><p>others) CO</p><p>poisoning,</p><p>thermal</p><p>burns,</p><p>necrotizing</p><p>soft-tissue</p><p>infections</p><p>n = 139 TG</p><p>age: 2 months—</p><p>18 years (mean</p><p>age: 7.7 years)</p><p>HBOT</p><p>standard</p><p>treatment</p><p>assessment based on</p><p>neurological</p><p>complications,</p><p>mortality, and degree</p><p>of soft tissue loss and</p><p>limb amputations</p><p>13</p><p>Grossman</p><p>(1978)</p><p>retrosp.</p><p>thermal</p><p>burns</p><p>n = 138 TG</p><p>n = 243 CG</p><p>age: 9 months—</p><p>80 years</p><p>- 2 HBO treatment</p><p>sessions per day at 2</p><p>ATA for 7 days, then</p><p>once a day</p><p>- session duration: 2</p><p>times a day for 45 min;</p><p>once a day for 90 min</p><p>standard</p><p>treatment</p><p>- children were</p><p>examined once a</p><p>day by a</p><p>pediatrician</p><p>- evaluation criteria</p><p>included ﬂuid</p><p>requirements,</p><p>duration of</p><p>hospitalization,</p><p>complication rate,</p><p>mortality rate</p><p>- positive results in 129 of</p><p>139 patients undergoing</p><p>HBO</p><p>[28]</p><p>- ﬂuid requirements</p><p>reduced by at least 30%</p><p>- shorter hospital stay</p><p>relative to the statistical</p><p>length of hospital stay:</p><p>by about 55% for burns</p><p>below 30%, by about</p><p>23% for burns from 30 to</p><p>60%, by about 12% for</p><p>burns above 60%</p><p>- the complication rate</p><p>decreased dramatically</p><p>- the mortality rate</p><p>decreased</p><p>[29]</p><p>Author Contributions: Conceptualization, A.P.M. and A.T.; methodology, A.P.M., K.N. and A.T.; for-</p><p>mal analysis, A.P.M. and I.D.; resources, A.P.M., A.T. and J.T.W.; writing—original draft preparation,</p><p>J.T.W., A.T. and K.N.; writing—review and editing, A.P.M. and K.N.; visualization, K.N.; supervision,</p><p>I.D.; project administration, A.P.M. and K.N. All authors have read and agreed to the published</p><p>version of the manuscript.</p><p>Funding: This research recived no external funding.</p><p>Conﬂicts of Interest: The authors declare no conﬂict of interest.</p><p>1.</p><p>2.</p><p>Solomon, J.J.; Heyman, B.; Ko, J.P.; Condos, R.; Lynch, D.A. CT of post-acute lung complications of COVID-19. Radiology 2021,</p><p>301, 383–395. [CrossRef] [PubMed]</p><p>Ceban, F.; Ling, S.; Lui, L.; Lee, Y.; Gill, H.; Teopiz, K.M.; Rodrigues, N.B.; Subramaniapillai, M.; Di Vincenzo, J.D.; Cao, B.; et al.</p><p>Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun.</p><p>2022, 101, 93–135. [CrossRef] [PubMed]</p><p>4.</p><p>5.</p><p>[CrossRef]</p><p>Ladhani, S.N.; Amin-Chowdhury, Z.; Davis, H.G.; Aiano, F.; Hayden, I.; Lacy, J.; Sinnathamby, M.; de Lusignan, S.; Demirjian, A.;</p><p>[CrossRef]</p><p>383, 187–190. [CrossRef]</p><p>7.</p><p>6.  Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in</p><p>China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA J. Am. Med.</p><p>Bi, Q.; Wu, Y.; Mei, S.; Ye, C.; Zou, X.; Zhang, Z.; Liu, X.; Wei, L.; Truelove, S.A.; Zhang, T.; et al. Epidemiology and transmission</p><p>of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect. Dis.</p><p>Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. Available online: Services.aap.org/en/</p><p>pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/2021 (accessed on 18 May</p><p>2021).</p><p>9.</p><p>8.</p><p>[CrossRef]</p><p>12.  Whittaker, E.; Bamford, A.; Kenny, J.; Kaforou, M.; Jones, C.E.; Shah, P.; Ramnarayan, P.; Fraisse, A.; Miller, O.; Davies, P.;</p><p>et al. Clinical Characteristics of 58 Children with a Pediatric Inﬂammatory Multisystem Syndrome Temporally Associated with</p><p>Shereen, M.A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Origin, transmission, and characteristics of</p><p>Senniappan, K.; Jeyabalan, S.; Rangappa, P.; Kanchi, M. Hyperbaric oxygen therapy: Can it be a novel supportive therapy in</p><p>13.</p><p>14.</p><p>15.  Ciesielska, N.; Sokołowski, R.; Popiel, A.; Kozakiewicz, M.; Sysakiewicz, M.; Buda, K.; K˛edziora-Kornatowska, K. The use of</p><p>7–26.</p><p>17.  Yildiz, L.A.; Gultekingil, A.; Kesici, S.; Bayrakci, B.; Teksam, O. Predictors of severe clinical course in children with carbon</p><p>18.  Neheman, A.; Rappaport, Y.; Verhovsky, G.; Bush, N.; Snodgrass, W.; Lang, E.; Zisman, A.; Efrati, S. Hyperbaric oxygen therapy</p><p>21.  Biddeci, G.; Bosco, G.; Varotto, E.; Corradin, M.; Geranio, G.; Tridello, G.; Pillon, M.; Carraro, E.; Garetto, G.; Assadi, R.; et al.</p><p>Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: Early diagnosis and new treatment strategies.</p><p>Anticancer. Res. 2019, 39, 1259–1266. [CrossRef]</p><p>22.  Teksam, O.; Sabuncuo ˘glu, S.; Girgin, G.; Özgüne¸s, H. Evaluation of oxidative stress and antioxidant parameters in children with</p><p>carbon monoxide poisoning. Hum. Exp. Toxicol. 2019, 38, 1235–1243. [CrossRef] [PubMed]</p><p>23.  Kawecki, M.; Knefel, G.; Szyma ´nska, B.; Nowak, M.; Siero ´n, A. Hyperbaric Oxygen Treatment in Burn Treatment Center, own</p><p>experience. Balneol. Pol. 2016, 4, 211–219.</p><p>24.  Yarar, C.; Yakut, A.; Akin, B.; Yildiz, E.; Dinleyici, C. Analysis of the features of acute carbon monoxide poisoning and hyperbaric</p><p>oxygen therapy in children. Turk. J. Pediatr. 2008, 50, 235–241. [PubMed]</p><p>25.  Bernbeck, B.; Christaras, A.; Krauth, K.; Lentrodt, S.; Strelow, H.; Schaper, J.; Janßen, G.; Mödder, U.; Göbel, U. Bone marrow</p><p>oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or Non-Hodgkin-lymphoma</p><p>treated with hyperbaric-oxygen-therapy (HBO): An approach to cure? BME/AON and hyperbaric oxygen therapy as a treatment</p><p>modality. Klin. Padiatr. 2004, 216, 370–378. [CrossRef] [PubMed]</p><p>Scherer, A.; Engelbrecht, V.; Bernbeck, B.; May, P.; Willers, R.; Göbel, U.; Mödder, U. MRI evaluation of aseptic osteonecrosis in</p><p>children over the course of hyperbaric oxygen therapy. RoFo Fortschr. Auf Geb. Rontgenstrahlen Bildgeb. Verfahr. 2000, 172, 798–801.</p><p>[CrossRef]</p><p>26.</p><p>27.  Chou, K.J.; Fisher, J.L.; Silver, E.J. Characteristics and outcome of children with carbon monoxide poisoning with and without</p><p>smoke exposure referred for hyperbaric oxygen therapy. Pediatr. Emerg. Care 2000, 16, 151–155. [CrossRef]</p><p>28.  Waisman, D.; Shupak, A.; Weisz, G.; Melamed, Y. Hyperbaric oxygen therapy in the pediatric patient: The experience of the Israel</p><p>Naval Medical Institute. Pediatrics 1998, 102, e53. [CrossRef]</p><p>30.  Neuman, T.S.; Thom, S.R. Physiology and Medicine of Hyperbaric Oxygen Therapy; Elsevier: Philadelphia, PA, USA, 2008.</p><p>31.  Oliaei, S.; Seyed Alinaghi, S.; Mehrtak, M.; Karimi, A.; Noori, T.; Mirzapour, P.; Shojaei, A.; MohsseniPour, M.; Mirghaderi, S.P.;</p><p>Alilou, S.; et al. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): A systematic review.</p><p>32.  Kjellberg, A.; Douglas, J.; Pawik, M.T.; Kraus, M.; Oscarsson, N.; Zheng, X.; Bergman, P.; Frånberg, O.; Kowalski, J.H.; Nyren,</p><p>S.P.; et al. Randomised, controlled, open label, multicentre clinical trial to explore safety and efﬁcacy of hyperbaric oxygen for</p><p>33.  Robbins, T.; Gonevski, M.; Clarc, C.; Baitule, S.; Sharma, K.; Magar, A.; Patel, K.; Sankar, S.; Kyrou, I.; Ali, A.; et al. Hyperbaric</p><p>e629–e632. [CrossRef] [PubMed]</p></div></body></html>